Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GSK PLC Sponsored ADR stock logo
GSK
GSK
$51.52
-0.3%
$51.74
$36.75
$61.69
$104.55B0.364.60 million shs4.53 million shs
Sanofi stock logo
SNY
Sanofi
$42.95
-0.3%
$43.41
$40.89
$52.68
$104.44B0.353.46 million shs2.60 million shs
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$16.85
-1.4%
$16.28
$12.99
$18.90
$54.76B-0.083.92 million shs3.15 million shs
Zoetis Inc. stock logo
ZTS
Zoetis
$77.13
-0.2%
$76.97
$71.47
$160.48
$32.40B0.735.53 million shs5.06 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GSK PLC Sponsored ADR stock logo
GSK
GSK
0.00%+0.67%-3.66%+0.15%+37.82%
Sanofi stock logo
SNY
Sanofi
0.00%-0.62%-0.19%-6.51%-7.85%
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
0.00%-0.81%+2.15%+2.83%+20.64%
Zoetis Inc. stock logo
ZTS
Zoetis
0.00%+2.72%+3.53%-32.26%-47.51%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GSK PLC Sponsored ADR stock logo
GSK
GSK
$51.52
-0.3%
$51.74
$36.75
$61.69
$104.55B0.364.60 million shs4.53 million shs
Sanofi stock logo
SNY
Sanofi
$42.95
-0.3%
$43.41
$40.89
$52.68
$104.44B0.353.46 million shs2.60 million shs
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$16.85
-1.4%
$16.28
$12.99
$18.90
$54.76B-0.083.92 million shs3.15 million shs
Zoetis Inc. stock logo
ZTS
Zoetis
$77.13
-0.2%
$76.97
$71.47
$160.48
$32.40B0.735.53 million shs5.06 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GSK PLC Sponsored ADR stock logo
GSK
GSK
0.00%+0.67%-3.66%+0.15%+37.82%
Sanofi stock logo
SNY
Sanofi
0.00%-0.62%-0.19%-6.51%-7.85%
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
0.00%-0.81%+2.15%+2.83%+20.64%
Zoetis Inc. stock logo
ZTS
Zoetis
0.00%+2.72%+3.53%-32.26%-47.51%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GSK PLC Sponsored ADR stock logo
GSK
GSK
2.10
Hold$53.002.88% Upside
Sanofi stock logo
SNY
Sanofi
2.47
Hold$49.5015.25% Upside
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
2.00
HoldN/AN/A
Zoetis Inc. stock logo
ZTS
Zoetis
2.41
Hold$118.3353.42% Upside

Current Analyst Ratings Breakdown

Latest ZTS, GSK, SNY, and TAK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/30/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Reiterated RatingHold
7/30/2026
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
DowngradeHold (C-)Sell (D+)
7/29/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
DowngradeBuy (B-)Hold (C+)
7/27/2026
Zoetis Inc. stock logo
ZTS
Zoetis
Lower Price TargetNeutral$99.00 ➝ $85.00
7/24/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Initiated CoverageNeutral
7/22/2026
Zoetis Inc. stock logo
ZTS
Zoetis
Lower Price TargetOverweight$115.00 ➝ $99.00
7/17/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
UpgradeStrong-Buy
7/9/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Reiterated RatingHold
7/8/2026
Sanofi stock logo
SNY
Sanofi
Set Price Target$49.00
7/6/2026
Zoetis Inc. stock logo
ZTS
Zoetis
Lower Price TargetBuy$140.00 ➝ $95.00
7/6/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
UpgradeReduceHold
(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GSK PLC Sponsored ADR stock logo
GSK
GSK
$43.07B2.42$5.98 per share8.61$10.32 per share4.99
Sanofi stock logo
SNY
Sanofi
$49.35B2.11$7.04 per share6.10$33.26 per share1.29
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$28.32B1.91$3.06 per share5.51$15.41 per share1.09
Zoetis Inc. stock logo
ZTS
Zoetis
$9.47B3.42$7.55 per share10.22$7.56 per share10.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GSK PLC Sponsored ADR stock logo
GSK
GSK
$7.54B$3.2016.1110.002.9614.56%43.23%11.60%N/A
Sanofi stock logo
SNY
Sanofi
$8.84B$1.9122.498.291.158.66%14.19%7.95%N/A
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
-$1.01B$0.3449.5411.23N/A3.80%10.87%5.32%N/A
Zoetis Inc. stock logo
ZTS
Zoetis
$2.67B$6.0312.7910.491.2127.80%66.85%18.79%8/6/2026 (Estimated)

Latest ZTS, GSK, SNY, and TAK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Zoetis Inc. stock logo
ZTS
Zoetis
$1.85N/AN/AN/A$2.50 billionN/A
5/7/2026Q1 2026
Zoetis Inc. stock logo
ZTS
Zoetis
$1.60$1.53-$0.07$1.42$2.30 billion$2.26 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.793.47%-7.86%55.94%N/A
Sanofi stock logo
SNY
Sanofi
$1.764.10%+6.46%92.15%N/A
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$0.482.85%-6.89%141.18%N/A
Zoetis Inc. stock logo
ZTS
Zoetis
$2.122.75%+20.11%35.16%14 Years

Latest ZTS, GSK, SNY, and TAK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/28/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.45153.36%8/14/20268/14/202610/8/2026
5/20/2026
Zoetis Inc. stock logo
ZTS
Zoetis
quarterly$0.532.78%7/20/20267/20/20269/1/2026
1/1/2100
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.42064.3%8/15/20258/15/202510/9/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GSK PLC Sponsored ADR stock logo
GSK
GSK
0.81
0.82
0.52
Sanofi stock logo
SNY
Sanofi
0.21
0.99
0.64
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
0.59
1.09
0.60
Zoetis Inc. stock logo
ZTS
Zoetis
2.80
3.15
1.91

Institutional Ownership

CompanyInstitutional Ownership
GSK PLC Sponsored ADR stock logo
GSK
GSK
15.74%
Sanofi stock logo
SNY
Sanofi
14.03%
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
9.17%
Zoetis Inc. stock logo
ZTS
Zoetis
92.80%

Insider Ownership

CompanyInsider Ownership
GSK PLC Sponsored ADR stock logo
GSK
GSK
10.00%
Sanofi stock logo
SNY
Sanofi
1.00%
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
0.04%
Zoetis Inc. stock logo
ZTS
Zoetis
0.22%
CompanyEmployeesShares OutstandingFree FloatOptionable
GSK PLC Sponsored ADR stock logo
GSK
GSK
66,8412.02 billion1.82 billionOptionable
Sanofi stock logo
SNY
Sanofi
74,8462.42 billion2.40 billionOptionable
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
47,0003.20 billion3.20 billionOptionable
Zoetis Inc. stock logo
ZTS
Zoetis
14,500419.23 million418.31 millionOptionable

Recent News About These Companies

Zoetis (ZTS) Growth Weakens Amid Softening Pet Care Demand 
Rathbones Group PLC Decreases Holdings in Zoetis Inc. $ZTS
Stifel Nicolaus Sticks to Their Hold Rating for Zoetis (ZTS)
Summitry LLC Invests $21.25 Million in Zoetis Inc. $ZTS
Janus Henderson Group PLC Trims Stake in Zoetis Inc. $ZTS

New MarketBeat Followers Over Time

Media Sentiment Over Time

GSK stock logo

GSK NYSE:GSK

$51.52 -0.17 (-0.33%)
Closing price 03:59 PM Eastern
Extended Trading
$51.98 +0.47 (+0.91%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Sanofi stock logo

Sanofi NASDAQ:SNY

$42.95 -0.13 (-0.30%)
Closing price 04:00 PM Eastern
Extended Trading
$42.92 -0.03 (-0.07%)
As of 07:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Takeda Pharmaceutical stock logo

Takeda Pharmaceutical NYSE:TAK

$16.84 -0.25 (-1.43%)
Closing price 03:59 PM Eastern
Extended Trading
$16.88 +0.04 (+0.21%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Zoetis stock logo

Zoetis NYSE:ZTS

$77.13 -0.16 (-0.21%)
Closing price 03:59 PM Eastern
Extended Trading
$77.36 +0.23 (+0.30%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.